Trials
Search / Trial NCT05649462

Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis

Launched by SECOND AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Dec 13, 2022

Trial Information

Current as of January 16, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • moderate-to-severe UC
  • Treated with Vedolizumab
  • Exclusion Criteria:
  • had recent supplementation of vitD3
  • pregnant
  • had cognitive/developmental disorders that affected their ability to complete the study procedures
  • had medical illness or therapies potentially affecting bone, nutrition or growth status
  • unknown or untested baseline serum 25(OH)D level

Trial Officials

Xia shenglong, Master

Principal Investigator

Second Affiliated Hospital of Wenzhou Medical University

About Second Affiliated Hospital Of Wenzhou Medical University

The Second Affiliated Hospital of Wenzhou Medical University is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent teaching hospital, it integrates clinical practice with innovative research and education, fostering a collaborative environment for healthcare professionals. The hospital is equipped with state-of-the-art facilities and a diverse range of specialized departments, enabling it to conduct comprehensive clinical trials across various medical fields. Its mission is to enhance healthcare outcomes through rigorous scientific inquiry and to contribute to the global body of medical research.

Locations

Wenzhou, Zhejiang, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials